|
 |
|
|
Jeongmin Kim, Ph.D.
|
|
Chief Executive Officer & Founder
|
|
|
|
Jeongmin Kim, CEO of DigmBio, is a distinguished authority in the realm of small molecules, acclaimed for his prolific career in pioneering new drug R&D endeavors across esteemed Korean pharmaceutical entities like LG Chemical, Green Cross Biopharma, and Jeil Pharmaceutical Co. With an extensive background spanning decades in cancer therapy and CNS diseases, notably in PARP inhibitors, Jeongmin brings unparalleled expertise to the forefront. Holding a Ph.D. in biochemistry from the University of Wisconsin-Madison, his leadership is poised to drive DigmBio towards groundbreaking advancements in medical innovation.
|
|
|
 |
|
|
Jae-Hoon Kang Ph.D
|
|
Chief Technology Officer
|
|
|
|
Jae-Hoon Kang assumes the role of Chief Technology Officer, leading pharmaceutical development and manufacturing endeavors at DigmBio. Prior to joining the company, Jae-Hoon previously served as Chief Executive Officer at Ildong Hyaltech, and the head of R&D at Ildong Pharmaceutical Co, a firm specializing in cancer therapies and antibiotics. Jae-Hoon is revered for his profound expertise in new drug R&D and global clinical trials, having been entrusted as a key committee member in reviewing and deciding on government grants and assistance for new drug R&D initiatives over decades. He earned his Ph.D. in chemistry from Sungkyunkwan University.
|
|
|
 |
|
|
Jung-Ho Kim Ph.D.
|
|
Chief Scientific Officer
|
|
|
|
Jung-Ho Kim serves as the Chief Scientific Officer, leading new drug development at DigmBio. Renowned for his pivotal role in developing and out-licensing Lazertinib to Yuhan during his tenure as CSO at Oscotec, alongside his colleagues, Dr. Kim has demonstrated exceptional leadership. Lazertinib was finally licensed to Janssen, a pharmaceutical company of Johnson and Johnson, with FDA approval pending following the completion of the global phase 3 clinical trial, Mariposa, targeting non-small cell lung cancer treatment. With extensive expertise in discovering and developing kinase inhibitors like Cevidoplenib, Denfivontinib, and Lazertinib, Jung-Ho Kim has made significant contributions to the field. He earned his Ph.D. in chemistry from the University of Illinois at Urbana-Champaign.
|
|
|
 |
|
|
Myung-Eun Jung Ph.D.
|
|
Managing Director, Head of Bio Division
|
|
|
|
Myung-Eun Jung leads as Head of the Bio Division at DigmBio, overseeing the research and development for new drug candidates. With a robust background, Myung-Eun previously contributed her expertise at Green Cross Biopharma for about 15 years. During her tenure, she held exclusive leadership roles and spearheaded various R&D initiatives, spanning small molecule, vaccines, plasma derivatives, and antibody therapies. Her comprehensive experience encompasses global clinical trials and regulatory approvals. Myung-Eun earned her Ph.D. in Neuroscience from Hallym University .
|
|
|
 |
|
|
Young-Choon Moon, Ph.D. / Chief Business Officer
|
|
Chief Business Officer
|
|
|
With a career spanning more than 30 years in pharmaceutical industry, Young-Choon Moon, Ph.D. has joined Digmbio as executive vice president and chief business officer.
Before joining Digmbio, Young-Choon spent 22 years as vice president at PTC Therapeutics and 5 years working as a Staff investigator at Vertex Pharmaceuticals. Young-Choon has co-authored more than 80 publications and patents in genetic disorders, oncology, and inflammatory diseases. He is one of the main contributors of development of translarna (DMD drug), risdiplam (SMA drug with Roche) and PTC518 (Huntington drug in Ph 1, licensed out to Novartis and paid $1.0 billion upfront and will pay up to $1.9 billion in development, regulatory and sales milestones. Young-Choon earned his doctorate of philosophy in organic chemistry from the University of Illinois at Urbana-Champaign. He completed his postdoctoral research at the Harvard University.
|
|
|
 |
|
|
Seong-Ryong Hwang
|
|
Chief Financial Officer
|
|
|
|
Seong-Ryong Hwang assumes the role of Chief Financial Officer at DigmBio, bringing over 34 years of experiences in finance and investment from Daewoo securities (Miraeasset securities), a prominent Korean securities firm. With expertise in equity underwriting and a CFA charter obtained in 2002, he brings a robust background in investment analysis and capital market operations, enriched by practical experience. Mr. Hwang, as CFO, is committed to bolstering the company's financial framework, with a particular emphasis on capital acquisition and strategic financial planning. He holds a Master's degree in English literature from Seoul National University.
|
|
